Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, aiming to improve the lives of patients and their families. The company's lead product candidate is designed to target the underlying causes of motor neuron disease and potentially other neurodegenerative conditions.

Amylyx Pharmaceuticals

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. 

Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Directorate General operational for Economy, Employment and Research

6K Venture Capital

Smedvig

Ifoghas Investments

Sambrinvest

Merieux Developpement

Meusinvest (Noshaq)

Kenneth Buckfire

Amyl Therapeutics

COM:AMYLTX

Amylyx Pharmaceuticals

Financials Not Available